NO20044191L - Kombinasjonsbehandlinqer for behandling av metyltioadenosin-fosforylasedefisiente celler - Google Patents
Kombinasjonsbehandlinqer for behandling av metyltioadenosin-fosforylasedefisiente cellerInfo
- Publication number
- NO20044191L NO20044191L NO20044191A NO20044191A NO20044191L NO 20044191 L NO20044191 L NO 20044191L NO 20044191 A NO20044191 A NO 20044191A NO 20044191 A NO20044191 A NO 20044191A NO 20044191 L NO20044191 L NO 20044191L
- Authority
- NO
- Norway
- Prior art keywords
- deficient cells
- mtap
- treatment
- mta
- methylthioadenosine
- Prior art date
Links
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 title abstract 6
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 title abstract 6
- 230000002950 deficient Effects 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000011284 combination treatment Methods 0.000 title 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 3
- GRSZFWQUAKGDAV-KQYNXXCUSA-L IMP(2-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-L 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 102000006933 Hydroxymethyl and Formyl Transferases Human genes 0.000 abstract 1
- 108010072462 Hydroxymethyl and Formyl Transferases Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001147 anti-toxic effect Effects 0.000 abstract 1
- OBQMLSFOUZUIOB-SHUUEZRQSA-N glycineamide ribonucleotide Chemical compound NCC(=O)N[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O OBQMLSFOUZUIOB-SHUUEZRQSA-N 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36164502P | 2002-03-04 | 2002-03-04 | |
| US43227502P | 2002-12-09 | 2002-12-09 | |
| PCT/IB2003/000615 WO2003074083A1 (fr) | 2002-03-04 | 2003-02-17 | Polytherapies pour traiter des cellules a deficience en methylthioadenosine phosphorylase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20044191L true NO20044191L (no) | 2004-09-30 |
Family
ID=27791683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044191A NO20044191L (no) | 2002-03-04 | 2004-09-30 | Kombinasjonsbehandlinqer for behandling av metyltioadenosin-fosforylasedefisiente celler |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040043959A1 (fr) |
| EP (1) | EP1482977A1 (fr) |
| KR (1) | KR20040091089A (fr) |
| AR (1) | AR038863A1 (fr) |
| AU (1) | AU2003206019A1 (fr) |
| BR (1) | BR0308222A (fr) |
| CA (1) | CA2477422A1 (fr) |
| IL (1) | IL163776A0 (fr) |
| NO (1) | NO20044191L (fr) |
| PA (1) | PA8568201A1 (fr) |
| PE (1) | PE20030907A1 (fr) |
| TW (1) | TW200304380A (fr) |
| UY (1) | UY27692A1 (fr) |
| WO (1) | WO2003074083A1 (fr) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004113328A1 (fr) * | 2003-06-25 | 2004-12-29 | Pfizer Inc. | Voie asymetrique convergente de synthese pour produire un compose intermediaire cle de la synthese d'un inhibiteur de garft |
| JP2005292087A (ja) * | 2004-04-05 | 2005-10-20 | Shionogi & Co Ltd | ５’−デオキシ−５’−メチルチオアデノシンに対する抗体 |
| US7981902B2 (en) * | 2006-06-28 | 2011-07-19 | Duquesne University Of The Holy Ghost | Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with FR type receptors |
| EP2192905A4 (fr) * | 2007-08-29 | 2010-11-10 | Adam Lubin | Procédé pour la thérapie sélective d'une maladie |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX358640B (es) | 2008-01-04 | 2018-08-29 | Intellikine Llc | Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas. |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| US9725479B2 (en) * | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| EP2571357B1 (fr) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Composés chimiques, compositions et procédés pour modulation de kinases |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| KR20130124959A (ko) | 2010-12-03 | 2013-11-15 | 에피자임, 인코포레이티드 | 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법 |
| BR112013013659B8 (pt) | 2010-12-03 | 2024-02-27 | Epizyme Inc | Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia |
| TWI546305B (zh) | 2011-01-10 | 2016-08-21 | 英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| WO2013012918A1 (fr) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composés hétérocycliques et leurs utilisations |
| AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| CA2846431A1 (fr) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Composes heterocycliques et leurs utilisations |
| EP2771012A4 (fr) * | 2011-10-24 | 2015-06-24 | Glaxosmithkline Ip No 2 Ltd | Nouveaux composés |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| US20150284422A1 (en) | 2012-08-10 | 2015-10-08 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| WO2014039839A1 (fr) | 2012-09-06 | 2014-03-13 | Epizyme, Inc. | Méthode de traitement de la leucémie |
| CN105102000B (zh) | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
| CN103073606B (zh) * | 2013-02-05 | 2016-05-18 | 中国医药研究开发中心有限公司 | 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法 |
| EP2968387A4 (fr) | 2013-03-15 | 2017-04-05 | Epizyme, Inc. | Procédés de synthèse de composés de purine substitués |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| MX389256B (es) | 2013-10-04 | 2025-03-20 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EA201691872A1 (ru) | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
| WO2015160975A2 (fr) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Polythérapies |
| EP3134411B1 (fr) * | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Dérivés de la purine en tant qu'inhibiteurs pour le traitement du cancer |
| WO2016054491A1 (fr) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| WO2016056606A1 (fr) * | 2014-10-07 | 2016-04-14 | 国立大学法人京都大学 | Dérivé benzoisothiazolopyrimidine et sel de ce dernier, et inhibiteur d'infection virale et médicament |
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| EA201892031A1 (ru) * | 2016-03-10 | 2019-02-28 | Янссен Фармацевтика Нв | Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5 |
| WO2017153186A1 (fr) | 2016-03-10 | 2017-09-14 | Janssen Pharmaceutica Nv | Analogues de nucléosides substitués destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
| WO2017161116A1 (fr) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k |
| CA2969295A1 (fr) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Derives de carbonucleosides substitues et leur utilisation comme inhibiteur de prmt5 |
| WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| EP3474856B1 (fr) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Therapies combinées |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| ES2872003T3 (es) | 2016-09-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Inhibidores espirobicíclicos de la interacción de menina-MLL |
| CN109715634B (zh) | 2016-09-14 | 2022-09-27 | 詹森药业有限公司 | Menin-mll相互作用的稠合二环抑制剂 |
| BR112019006414A2 (pt) | 2016-10-03 | 2019-06-25 | Janssen Pharmaceutica Nv | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 |
| WO2018065365A1 (fr) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
| KR102513564B1 (ko) | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| CN110382707A (zh) | 2017-02-27 | 2019-10-25 | 詹森药业有限公司 | 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途 |
| WO2019110734A1 (fr) | 2017-12-08 | 2019-06-13 | Janssen Pharmaceutica Nv | Nouveaux analogues spirobicycliques |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN109369758B (zh) * | 2018-11-02 | 2021-04-13 | 哈尔滨商业大学 | 5′-(6-氯烟酰酯)-3′-脱氧腺苷的合成方法及其应用 |
| CN109111445B (zh) * | 2018-11-02 | 2020-12-18 | 哈尔滨商业大学 | 5’-呋喃甲酰酯-3’-脱氧腺苷的合成方法及应用 |
| WO2020190073A1 (fr) * | 2019-03-20 | 2020-09-24 | 한국화학연구원 | Composition pharmaceutique comprenant un nouveau composé hétérocyclique azolopyrimidine en tant que principe actif |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| CR20220012A (es) | 2019-06-12 | 2022-03-11 | Janssen Pharmaceutica Nv | Nuevos intermedios espirobiciclicos |
| MX2022007652A (es) | 2019-12-19 | 2022-09-23 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal. |
| WO2021254529A1 (fr) * | 2020-07-14 | 2021-12-23 | 江苏先声药业有限公司 | Composé bicyclique |
| LV15670B (lv) * | 2021-03-10 | 2023-11-20 | Latvijas Organiskās Sintēzes Institūts | Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori |
| US20240208944A1 (en) * | 2021-04-19 | 2024-06-27 | Emory University | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition |
| CN113603721B (zh) * | 2021-06-21 | 2023-12-01 | 重庆文理学院 | 一种合成saicar的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8625019D0 (en) * | 1986-10-18 | 1986-11-19 | Wellcome Found | Compounds |
| CA2151588C (fr) * | 1992-12-16 | 2002-03-19 | Michael D. Varney | 5-thiapyrimidinone et 5-selenopyrimidinone substitues ayant des proprietes antiproliferatives |
| US5945427A (en) * | 1995-06-07 | 1999-08-31 | Agouron Pharmaceuticals, Inc. | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds |
| ATE201877T1 (de) * | 1993-01-29 | 2001-06-15 | Agouron Pharma | Kondensierte heterocyclische glutaminsäurederivate als antiproliferative mittel |
| US5594139A (en) * | 1993-01-29 | 1997-01-14 | Agouron Pharmaceuticals, Inc. | Processes for preparing antiproliferative garft-inhibiting compounds |
| US5840505A (en) * | 1993-12-29 | 1998-11-24 | The Regents Of The University Of California | Method for inhibiting adenylosuccinate synthetase activity in methylthioadenosine phosphorylase deficient cells |
| US5942393A (en) * | 1993-12-29 | 1999-08-24 | The Regents Of The University Of California | Method for the detection of the presence or absence of methylthioadenosine phosphorylase (MTASE) in a cell sample by detection of the presence or absence of MTASE encoding nucleic acid in the cell sample |
| US5608082A (en) * | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
| ES2201079T3 (es) * | 1994-07-28 | 2004-03-16 | Agouron Pharmaceuticals, Inc. | Compuestos utiles como agentes antiproliferativos e inhibidores de garft. |
-
2003
- 2003-02-14 US US10/367,366 patent/US20040043959A1/en not_active Abandoned
- 2003-02-17 BR BR0308222-9A patent/BR0308222A/pt not_active Application Discontinuation
- 2003-02-17 AU AU2003206019A patent/AU2003206019A1/en not_active Abandoned
- 2003-02-17 EP EP03702902A patent/EP1482977A1/fr not_active Withdrawn
- 2003-02-17 IL IL17377603A patent/IL163776A0/xx unknown
- 2003-02-17 KR KR10-2004-7013707A patent/KR20040091089A/ko not_active Ceased
- 2003-02-17 WO PCT/IB2003/000615 patent/WO2003074083A1/fr not_active Ceased
- 2003-02-17 CA CA002477422A patent/CA2477422A1/fr not_active Abandoned
- 2003-02-28 UY UY27692A patent/UY27692A1/es not_active Application Discontinuation
- 2003-02-28 PE PE2003000205A patent/PE20030907A1/es not_active Application Discontinuation
- 2003-02-28 PA PA20038568201A patent/PA8568201A1/es unknown
- 2003-03-03 AR ARP030100700A patent/AR038863A1/es not_active Application Discontinuation
- 2003-03-03 TW TW092104399A patent/TW200304380A/zh unknown
-
2004
- 2004-09-30 NO NO20044191A patent/NO20044191L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20030907A1 (es) | 2003-10-29 |
| TW200304380A (en) | 2003-10-01 |
| IL163776A0 (en) | 2005-12-18 |
| AR038863A1 (es) | 2005-02-02 |
| PA8568201A1 (es) | 2003-11-12 |
| AU2003206019A1 (en) | 2003-09-16 |
| BR0308222A (pt) | 2005-02-09 |
| KR20040091089A (ko) | 2004-10-27 |
| WO2003074083A1 (fr) | 2003-09-12 |
| EP1482977A1 (fr) | 2004-12-08 |
| CA2477422A1 (fr) | 2003-09-12 |
| UY27692A1 (es) | 2003-10-31 |
| US20040043959A1 (en) | 2004-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20044191L (no) | Kombinasjonsbehandlinqer for behandling av metyltioadenosin-fosforylasedefisiente celler | |
| NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
| WO2006130627A3 (fr) | Methodes de traitement de l'hepatite c | |
| MY140748A (en) | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy | |
| NO20056252L (no) | Terapeutiske og profylaktiske metoder for neuromuskulaere lidelser | |
| NO20051048L (no) | Terapeutisk humant anti-IL-1R1 monoklonalt antistoff | |
| NO20024921L (no) | Kombinasjon av organiske forbindelser | |
| NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
| NO20052578L (no) | Kombinert administrering av et indolinon med et kjemoterapeutisk middel for celleproliferasjonslidelser | |
| SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
| WO2004041867A3 (fr) | Procede d'administration de polypeptides therapeutiques et polypeptides associes | |
| NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
| DK0828728T3 (da) | Phenyldihydrobenzofuraner | |
| NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
| EP1482959A4 (fr) | Compositions et methodes de traitement de troubles cutanes | |
| ATE376445T1 (de) | Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid- analoge | |
| EP1348466A3 (fr) | Méthode de traitement du douleur avec adenosine tetraphosphates | |
| DE59610031D1 (de) | Cyclohexyldihydrobenzofurane | |
| WO2004052236A3 (fr) | Methodes et compositions de traitement de l'otite moyenne | |
| MXPA04010307A (es) | Derivados 5-oxo y 5-tio de 5h-indeno`1,2-bipiridina con enlace al receptor a2a de la adenosina y actividad inhibidora de la fosfodiesterasa para el tratamiento de trastornos neurodegenerativos y enfermedades relacionadas con la inflamacion. | |
| WO2006014913A3 (fr) | Inhibiteurs de 5'-methylthioadenosine phosphorylase et 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase | |
| WO2004024064A8 (fr) | Compositions et methodes de diagnostic et de traitement de tumeurs | |
| BR0008781A (pt) | Terapia combinada de inibidor de enzima conversora de angiotensina e antagonista de aldosterona epóxi-esteroidal para tratamento de doença cardiovascular | |
| WO2006055970A3 (fr) | Traitement d'amelioration de troubles medies par hif-1 faisant appel a des agonistes du recepteur de l'adenosine a3 | |
| NO20052579L (no) | Derviater av (6,7-dihydro-5h-imidazo(i,2-a) imidazol-3-sulfonylamino)-pro pionamid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |